The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?
Gleissberg
V
V
Newham Healthcare NHS Trust, Shrewsbury Centre, London, UK. ginig@ibm.net
D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D010349:Patient Compliance; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D006113:United Kingdom; D014481:United States
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin